Neurotech Company Reaches Major Agreement With FDA For Stroke Treatment
Helius Medical Technologies Aligns with FDA on Stroke Treatment Program: A New Hope for Patients.
Disclaimer: This post includes affiliate links. If you purchase anything through these affiliated links, the author/website may earn a commission.
A significant development in the medical technology industry has just been announced. Helius Medical Technologies, Inc, a neurotech company focused on neurological wellness, has recently disclosed that they have reached an agreement with the U.S. Food and Drug Administration (FDA) on a registrational program for the treatment of stroke patients. This is a significant step forward for stroke sufferers, potentially paving the way for more effective treatments and improved patient outcomes.
Helius' Portable Neuromodulation Stimulator (PoNS) device is at the center of this program. It's a non-invasive device that delivers mild electrical stimulation to the surface of the tongue to promote neuroplasticity, the brain's ability to form new neural connections. This could be a game-changer in the treatment of stroke patients, offering a new approach that could complement existing rehabilitation therapies.
The registrational program will consist of two double-blind, randomized, controlled trials. The first will evaluate the safety and effectiveness of the PoNS treatment in reducing motor deficits in chronic stroke patients, while the second will assess its impact on cognitive deficits. Both studies will be crucial in determining the full potential of this innovative treatment.
This development is particularly significant considering the scale of the problem Helius is attempting to address. According to the American Stroke Association, stroke is the fifth leading cause of death in the U.S., and a leading cause of severe long-term disability.
It's worth noting that Helius' approach aligns with current trends in medical technology. The industry is increasingly focusing on neuroplasticity and non-invasive treatments, recognizing their potential to improve patient outcomes without the risks associated with surgery or medication.
In conclusion, Helius Medical Technologies' alignment with the FDA on their registrational program for stroke treatment represents a significant step forward in the field of neurological wellness. This could potentially open up a new pathway for stroke patients, offering hope for more effective treatments and improved quality of life.
While we wait for the results of the registrational program, it's clear that this development is one to watch closely. If successful, it could revolutionize the way we treat stroke patients, marking a major milestone in medical technology.
As an investor it's important to stay updated with major news. Get real-time stock market alerts and research by creating an account here.
Sources: